论文部分内容阅读
目的探讨化疗前使用G-CSF治疗急性髓细胞白血病(AML)的临床意义。方法随机选择26例初治急性髓细胞白血病患者,化疗前给予惠尔血(日本麒麟公司产品)75μg/d,连用3d,继之联合化疗,观察化疗1周后骨髓白血病细胞减少的程度、1疗程缓解情况及相关并发症,与随机对照组相比较。结果治疗组化疗后1周骨髓白血病细胞减少50%以上的比率、一疗程完全缓解率与对照组相比均有显著性统计学意义(P<0.01),骨髓抑制程度、感染、出血等相关并发症未见明显增加(P>0.05)。结论急性髓细胞白血病化疗前应用小剂量G-CSF能提高其疗效,且毒副反应不增加。
Objective To investigate the clinical significance of G-CSF in the treatment of acute myeloid leukemia (AML) before chemotherapy. Methods Twenty-six patients with newly diagnosed acute myeloid leukemia were randomly selected. Before chemotherapy, 75 μg / d of Whirlpool (a product of Kirin Corporation of Japan) was given for three consecutive days followed by combination chemotherapy to observe the degree of myeloid leukemia reduction 1 week after chemotherapy Course of remission and related complications, compared with the randomized control group. Results Compared with the control group, the complete remission rate of the treatment group was significantly lower than that of the control group (P <0.01), the degree of myelosuppression, infection, bleeding and other related complications No significant increase in disease (P> 0.05). Conclusion Acute myelocytic leukemia with low dose of G-CSF before chemotherapy can improve its curative effect, and the toxicity does not increase.